|
99 Companies |
|
136 Products |
|
136 Products |
|
121 Mechanisms of Action |
|
5 Trials |
|
1112 News |
|
| «12...567891011121314151617» |
- | gefitinib / Generic mfg.
Trial completion, Metastases: ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P2, N=51, Completed, Sponsor: University of Chicago
No longer recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion, Metastases: SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- exatecan mesylate (DX-8951f) / Daiichi Sankyo
Trial completion, Metastases: DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Suspended --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Suspended --> Completed Active, not recruiting --> Completed
- | Trial completion: Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation (clinicaltrials.gov) - Feb 19, 2014
P2, N=22, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion, Metastases: Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=70, Completed, Sponsor: City of Hope Medical Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | isotretinoin / Generic mfg.
Trial completion: Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Hoag Memorial Hospital Presbyterian
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: SGChirIPOM: Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM) (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=348, Completed, Sponsor: Cantonal Hospital of St. Gallen
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Enrollment closed: PRET: Patients Prone to Recurrence After Endovascular Treatment (clinicaltrials.gov) - Feb 12, 2014
P4, N=500, Active, not recruiting, Sponsor: Centre hospitalier de l'Universit
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- Trial termination: Anal Fistula Plug for High-type Anal Fistulae (clinicaltrials.gov) - Feb 11, 2014
P=N/A, N=10, Terminated, Sponsor: Chinese University of Hong Kong
Recruiting --> Active, not recruiting Recruiting --> Terminated; No financial support
- Enrollment change: Anal Fistula Plug for High-type Anal Fistulae (clinicaltrials.gov) - Feb 11, 2014
P=N/A, N=10, Terminated, Sponsor: Chinese University of Hong Kong
Recruiting --> Terminated; No financial support N=20 --> 10
- | Salofalk prolonged-release granules (mesalazine gastro-resistant prolonged-release granules) / Dr Falk
Enrollment change: Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis (clinicaltrials.gov) - Feb 9, 2014
P3, N=330, Terminated, Sponsor: Dr. Falk Pharma GmbH
N=20 --> 10 N=720 --> 330
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Enrollment change: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy (clinicaltrials.gov) - Feb 6, 2014
P3, N=27, Completed, Sponsor: Takeda
N=720 --> 330 N=160 --> 27
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Enrollment change: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy (clinicaltrials.gov) - Feb 6, 2014
P3, N=30, Completed, Sponsor: Takeda
N=160 --> 27 N=175 --> 30
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Trial completion: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy (clinicaltrials.gov) - Feb 6, 2014
P3, N=27, Completed, Sponsor: Takeda
N=175 --> 30 Recruiting --> Completed
- || Takecab (vonoprazan) / Takeda, Phathom Pharma
Trial completion: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy (clinicaltrials.gov) - Feb 6, 2014
P3, N=30, Completed, Sponsor: Takeda
Recruiting --> Completed Recruiting --> Completed
- paclitaxel / Generic mfg.
New P1 trial: Reirradiation With Concurrent Paclitaxel for Breast Cancer (clinicaltrials.gov) - Feb 6, 2014
P1, N=18, Not yet recruiting, Sponsor: University of Kentucky
- midazolam hydrochloride / Generic mfg.
Trial completion, Surgery: RAFPELS: Prospective Randomized Trial Comparing the New Endovenous Procedures Versus Conventional Surgery for Varicose Veins Due to Great Saphenous Vein Incompetence (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=540, Completed, Sponsor: Uppsala University
Recruiting --> Completed Recruiting --> Completed
- Trial completion, Surgery: Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery (clinicaltrials.gov) - Jan 29, 2014
P2, N=60, Completed, Sponsor: Meshalkin Research Institute of Pathology of Circulation
Recruiting --> Completed Recruiting --> Completed
- Enrollment closed: Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition? (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: Atlantic Health System
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: WiLLoW: Fear of Recurrence Pilot Intervention for Women With Breast Cancer (clinicaltrials.gov) - Jan 22, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting N=40 --> 28
- Trial completion: WiLLoW: Fear of Recurrence Pilot Intervention for Women With Breast Cancer (clinicaltrials.gov) - Jan 22, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
N=40 --> 28 Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Surgery, Post-surgery: ACCRA-HN: Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (clinicaltrials.gov) - Jan 21, 2014
P2, N=80, Completed, Sponsor: Heinrich-Heine University, Duesseldorf
Recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment closed: THORN: Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators. (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=1750, Active, not recruiting, Sponsor: Biotronik SE & Co. KG
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=4, Completed, Sponsor: Clinical Research Office of the Endourological Society
Recruiting --> Active, not recruiting N=40 --> 4
- Trial completion: Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=4, Completed, Sponsor: Clinical Research Office of the Endourological Society
N=40 --> 4 Enrolling by invitation --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (clinicaltrials.gov) - Jan 12, 2014
P3, N=84, Active, not recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- | Trial completion: Post-operative Crohn's Endoscopic Recurrence Study (clinicaltrials.gov) - Jan 9, 2014
P3, N=175, Completed, Sponsor: University of Melbourne
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | New P4 trial: Predictors of the Response and Relapse/Recurrence After ECT for Depressed Patients (clinicaltrials.gov) - Jan 8, 2014
P4, N=170, Completed, Sponsor: Kaohsiung Kai-Suan Psychiatric Hospital
- | New P4 trial: Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV (clinicaltrials.gov) - Jan 7, 2014
P4, N=2018, Recruiting, Sponsor: Seoul National University Bundang Hospital
- tranexamic acid oral / Generic mfg.
Trial withdrawal: Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis (clinicaltrials.gov) - Jan 5, 2014
P3, N=0, Withdrawn, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- tranexamic acid oral / Generic mfg.
Enrollment change: Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis (clinicaltrials.gov) - Jan 5, 2014
P3, N=0, Withdrawn, Sponsor: Seoul National University Hospital
Not yet recruiting --> Withdrawn N=308 --> 0
- cisplatin / Generic mfg., etoposide IV / Generic mfg.
Enrollment closed, IO biomarker: Preoperative Treatment of Patients With High Risk Thymoma (clinicaltrials.gov) - Dec 30, 2013
P2, N=30, Active, not recruiting, Sponsor: Valley Health System
N=308 --> 0 Recruiting --> Active, not recruiting
- Trial withdrawal: Prognostic Value of Stem Cell Related Markers (clinicaltrials.gov) - Dec 21, 2013
P=N/A, N=0, Withdrawn, Sponsor: The Baruch Padeh Medical Center, Poriya
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Enrollment change: Prognostic Value of Stem Cell Related Markers (clinicaltrials.gov) - Dec 21, 2013
P=N/A, N=0, Withdrawn, Sponsor: The Baruch Padeh Medical Center, Poriya
Not yet recruiting --> Withdrawn N=100 --> 0
- New P2 trial, HEOR, Adherence: Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients (clinicaltrials.gov) - Dec 18, 2013
P2, N=50, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Trial initiation date: ABSTACK: Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=816, Completed, Sponsor: Hvidovre University Hospital
N=100 --> 0 Initiation date: Aug 2013 --> Nov 2013
- Enrollment change: ABSNOME: The Effect of Sutures Versus Mesh in Umbilical Hernia Repair (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=1313, Completed, Sponsor: Hvidovre University Hospital
Initiation date: Aug 2013 --> Nov 2013 N=2000 --> 1313
- Trial completion: ABSNOME: The Effect of Sutures Versus Mesh in Umbilical Hernia Repair (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=1313, Completed, Sponsor: Hvidovre University Hospital
N=2000 --> 1313 Enrolling by invitation --> Completed
- | New P4 trial: DETECT: The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease (clinicaltrials.gov) - Dec 11, 2013
P4, N=136, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- || Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
New P3 trial: Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients (clinicaltrials.gov) - Dec 11, 2013
P3, N=56, Not yet recruiting, Sponsor: Seoul National University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial withdrawal, Combination therapy, Metastases: Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas (clinicaltrials.gov) - Dec 10, 2013
P2, N=0, Withdrawn, Sponsor: University of Alabama at Birmingham
Enrolling by invitation --> Completed Completed --> Withdrawn
- | Biomarker, New P2 trial, Surgery: Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery (clinicaltrials.gov) - Dec 8, 2013
P2, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
- | New P1/2 trial: Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer (clinicaltrials.gov) - Dec 8, 2013
P1/2, N=37, Completed, Sponsor: Abnoba Gmbh
- ||||| Enrollment closed: A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients (clinicaltrials.gov) - Dec 7, 2013
P3, N=80, Active, not recruiting, Sponsor: SK Chemicals Co.,Ltd.
Completed --> Withdrawn Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Dec 7, 2013
P2, N=54, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Surgery: Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer (clinicaltrials.gov) - Dec 5, 2013
P2, N=100, Active, not recruiting, Sponsor: Seoul National University Bundang Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- artemether/lumefantrine / Generic mfg.
New P4 trial: PCT: Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine (clinicaltrials.gov) - Nov 26, 2013
P4, N=45, Completed, Sponsor: Muhimbili University of Health and Allied Sciences
- Surgery: Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=30, Completed, Sponsor: National Cancer Institute (NCI)